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Summary 1 
 2 
Sleep and circadian abnormalities are prevalent and burdensome manifestations of diverse 3 
neuro-immune diseases, and may aggravate the course of several neuropsychiatric disorders. 4 
The underlying pathophysiology of sleep abnormalities across neuropsychiatric disorders 5 
remains unclear, and may involve the inter-play of several clinical variables and mechanistic 6 
pathways. In this review, we propose a heuristic framework in which reciprocal interactions 7 
of immune, oxidative and nitrosative stress, and mitochondrial pathways may drive sleep 8 
abnormalities across potentially neuroprogressive disorders. Specifically, it is proposed that 9 
systemic inflammation may activate microglial cells and astrocytes in brain regions involved 10 
in sleep and circadian regulation. Activated glial cells may secrete pro-inflammatory 11 
cytokines (for example, interleukin-1 beta and tumor necrosis factor alpha), nitric oxide and 12 
gliotransmitters, which may influence the expression of key circadian regulators (e.g. the 13 
CLOCK gene). Furthermore, sleep disruption may further aggravate oxidative and 14 
nitrosative, peripheral immune activation, and (neuro) inflammation across these disorders in 15 
a vicious pathophysiological loop. This review will focus on chronic fatigue syndrome, 16 
bipolar disorder, and multiple sclerosis as exemplars of neuro-immune disorders. We 17 
conclude that novel therapeutic targets exploring immune and oxidative & nitrosative 18 
pathways (p.e. melatonin and molecular hydrogen) hold promise in alleviating sleep and 19 
circadian dysfunction in these disorders. 20 
Keywords: chronic fatigue syndrome; bipolar disorder; multiple sclerosis; sleep; 21 
inflammation; oxidative stress 22 
 23 
 24 
 25 
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Abbreviations Used: 1 
AMPA α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid 
AMPK Adenosine monophosphate kinase 
ATP Adenosine triphosphate 
BBB Blood brain barrier 
BD Bipolar disorder 
cAMP Cyclic adenosine monophosphate 
CFS Chronic fatigue syndrome 
cGMP Cyclic guanosine monophosphate 
CLOCK Circadian Locomotor Output Cycles Kaput 
CREB Cyclic adenosine monophosphate response 
element-binding protein 
CSD Chronic Sleep Disruption 
IL Interleukin 
iNOS Inducible nitric oxide synthase 
LPS Lipopolysaccharides 
MAP Mitogen activated protein 
MS Multiple sclerosis 
NADH Nicotinamide adenine dinucleotide 
 
NF-κB Nuclear factor kappa-light-chain enhancer of 
activated B cells 
NMDA N-methyl-D-aspartate 
NO Nitric oxide 
NOS Nitric oxide synthase 
nREM Non-Rapid Eye Movement 
NSF N-ethylamide-sensitive factor 
O&NS Oxidative and nitrosative stress 
PER Period 
PGD2 Prostaglandin D2 
PIC Pro-inflammatory cytokines 
PKA Protein kinase A 
PMBC Peripheral mononuclear blood cells 
REM Rapid Eye Movement 
RNS Reactive nitrogen species 
ROS Reactive oxygen species 
SCN Suprachiasmatic Nucleus 
SNAP Synaptosomal-associataed protein 
SNARE N-ethylmaleimide-sensitive factor 
attachment protein receptors 
STAT Signal transducer and activator of 
transcription 
SWS Slow wave sleep 
Th T helper 
TLR Toll-like receptor  
TNF-α Tumor Necrosis Factor-α 
UCP Uncoupling protein 
VAMP Vesicle-associated membrane protein 
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While the importance of sleep in neuropsychiatric illnesses is indisputable, it is only 1 
recently that sleep and circadian mechanisms linked to neuropsychiatric diseases have been 2 
investigated at the cellular and molecular levels [1, 2]. Sleep has a role in the regulation of 3 
protein synthesis related to synaptic plasticity, with the rates of synaptic protein synthesis 4 
correlating with the amount of rapid eye movement (REM) relative to non-REM (NREM) 5 
sleep [3, 4]. In addition, sleep plays a regulatory role in immune function. For example, sleep 6 
may regulate the transcription and translation of pro-inflammatory and anti-inflammatory 7 
networks [5]. Interestingly, pro-inflammatory cytokines such as tumor necrosis factor-α 8 
(TNF-α), interleukin (IL)-1 and IL-6 have sleep-regulating functions, and several other 9 
immune and pro-inflammatory cellular classes seem to influence sleep [6]. Sleep exerts a 10 
regulatory role in maintaining the balance between T helper (Th) 1 and Th2 lymphocytes, 11 
their count in the circulation, the activity of effector and regulatory T cells, natural killer 12 
cells, and the number and function of antigen presenting cells [5, 7]. Further, sleep influences 13 
the immune system by modulating the activity of transcription factors that regulate and 14 
activate immune and inflammatory responses such as cyclic adenosine monophosphate 15 
(cAMP), mitogen activated protein (MAP) kinases, cAMP response element-binding protein 16 
(CREB) and nuclear factor kappa-light-chain enhancer of activated B cells (NF-κB) [8, 9].  17 
 Chronic sleep disruption (CSD) may increase the activity of the sympathetic nervous 18 
system, and leads to the disruption of the circadian clock in the periphery and in the brain 19 
[10]. At the cellular and molecular levels, CSD is associated with peripheral inflammation 20 
and immune dysfunction evidenced by increased serum levels of IL-1, TNF-α, IL-6 and IL-21 
17 and altered numbers and activity of macrophages and natural killer cells [11, 12]. Other 22 
adverse effects stemming from CSD extend to neuroinflammation, accompanied by changes 23 
in glial cell morphology and physiology [13] and compromised neuronal glial signalling [14]. 24 
Some of these effects also appear to be mediated by impaired cAMP-protein kinase A (PKA) 25 
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signalling, decreased CREB-mediated gene expression and reduced N-methyl-D-aspartate 1 
(NMDA) subunit expression at post-synaptic membranes [15]. 2 
Sleep disruption induces transcriptional changes in genes in mammalian brains which 3 
differ during acute or chronic sleep disruption. For example, acute sleep disruption results in 4 
an up-regulation of genes governing energy metabolism, antioxidant defences and neural 5 
function (reviewed in [16]). Such transcriptional changes are evidenced by increased levels of 6 
nuclear factor erythroid 2–related factor 2, nicotinamide adenine dinucleotide (NADH), 7 
complex I and complex IV enzymes of the electron transport chain, Sirtuin-3 oxidative 8 
phosphorylation, adenosine triphosphate (ATP) production and uncoupling proteins (UCP), 9 
notably UCP-2 [17-19]. However, in CSD, opposite effects are reported. For example, Zhao 10 
and colleagues reported  mitochondrial dysfunction in the frontal lobe, evidenced by reduced 11 
levels of cytochrome C oxidase, mitochondrial membrane potential, and ATP production 12 
[20]. Similarly, Zhang and colleagues who reported evidence of low sirtrulin-3 levels with a 13 
reduction in oxidative phosphorylation and ATP production together with evidence of 14 
neuronal loss in the locus coeruleus [21]. Other detrimental consequences of sleep 15 
deprivation include an up-regulation of the mitochondrial and endoplasmic reticulum protein 16 
unfolding response [22, 23] and up-regulation of UCP-2, thus uncoupling oxidative 17 
phosphorylation from ATP generation [21]. Finally, reduced levels of electron transport chain 18 
complexes I, II and III in the prefrontal cortex, hippocampus, striatum and hypothalamus 19 
during sleep deprivation have also been observed [24].  20 
Accumulating evidence suggests that the balance of sleep and wakefulness plays a 21 
significant role in regulating the production of reactive oxygen and nitrogen species (ROS 22 
and RNS, respectively) and the redox environment of the cell [25]. As the quality and 23 
quantity of sleep also influences the rates of oxidative phosphorylation and glycolysis [26, 24 
27], it is unsurprising that a large body of evidence exists to link sleep disruption to the 25 
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development and exacerbation of neuro-immune disorders. Figure 1 provides a wide-angle 1 
lens view of the effects of chronic sleep deprivation on pathways relevant to neuro-immune 2 
disorders. 3 
<Please insert Figure 1 here> 4 
Sleep deprivation is commonly seen in patients with neurodegenerative diseases, 5 
including multiple sclerosis (MS) [28]. Some authors have suggested that this phenomenon 6 
results from neural disorganisation and destruction with advancing disease [29]. Chronic 7 
sleep disturbances are also seen in patients with major psychiatric illnesses, particularly 8 
bipolar disorder (BD) [30], and in many patients diagnosed with chronic fatigue syndrome 9 
(CFS) [31]. This consistent pattern of sleep disruption in seemingly disparate illnesses point 10 
to possible shared underlying mechanisms. 11 
This is particularly relevant because over the past three decades, the adoption of a 12 
modern urban lifestyle led to a constant decrease in total sleeping time often referred to as an 13 
‘epidemic of sleep restriction’. For example, in the US and in Europe up to 20% of the 14 
population works at night which often leads to sleep deprivation [32]. This scenario of sleep 15 
deprivation may increase the risk and alter the course of psychiatric disorders although this 16 
field awaits more systematic investigation. For example, sleep loss may trigger episodes in a 17 
subset of patients with BD [33]. Likewise, sleep and circadian disturbances are well-known 18 
manifestations of BD during major affective episodes [34]. Furthermore, it has been shown 19 
that sleep deprivation leads to manic-like behaviours in mice, which were associated with 20 
cytokine and oxidative stress alterations in the brain and periphery of mice [35]. Interestingly, 21 
lithium which is a first-line agent for the treatment of BD prevented those behavioural and 22 
neurochemical alterations induced by sleep deprivation [35]. 23 
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Accumulating evidence point to significant sleep-immune interactions [12]. For 1 
example, in humans, infections with rhinoviruses decrease sleeping times [36]. Furthermore, 2 
it was recently demonstrated that lymphocyte circadian clocks may control lymph node 3 
trafficking and adaptive immune responses [37]. Perhaps not surprisingly sleep deprivation is 4 
now known to alter the number, dynamics and function of immune cells in humans and 5 
experimental animals as discussed below (see also Ref. [38] for a recent review on the 6 
reciprocal interactions of sleep and innate immunity).      7 
It is interesting to note that inflammation and oxidative stress, which appears to be a 8 
common element in the pathophysiology of the aforementioned illnesses [39, 40], have the 9 
capacity to disrupt levels of key players in the regulation of sleep homeostasis namely IL-1β, 10 
TNF-α, adenosine, and nitric oxide through activating microglia and astrocytes [40, 41]. In 11 
this review, we aim to detail mechanisms whereby chronic immune aberrations and oxidative 12 
stress could lead to chronic sleep disruption and chronic abnormalities in the transcription of 13 
genes whose activity is regulated by the circadian clock machinery. Furthermore, we will 14 
critically review evidence that mechanisms related to immune and oxidative stress pathways 15 
may underpin sleep disturbances in CFS, BD and MS as exemplars of neuropsychiatric 16 
disorders with characteristic sleep abnormalities.  17 
Section 2. Role of IL-1β, TNF-α, adenosine and nitric oxide in the regulation of seep 18 
homeostasis. 19 
2.1. The Role of IL-1β and TNF-α in the Regulation of Sleep Homeostasis 20 
Multiple lines of evidence have demonstrated indirect and direct effects of IL-1β and 21 
TNF-α and their receptors in the homeostatic regulation of sleep architecture and duration. 22 
Elevated levels of these cytokines are characteristic of systemic inflammation, and trigger a 23 
cascade of pro-inflammatory cytokine synthesis through effects at least partly mediated by 24 
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NF-κB, thus playing a crucial immunoregulatory role [42]. TNF-α and IL-1β act on neurons 1 
within localised neural assemblies (such as cortical columns) and have the capacity to change 2 
their electrical properties and receptor activity [6, 43]. These changes lead to alterations in the 3 
output and input activity of such neurons including provoking a shift to a sleep state [6, 44]. 4 
Importantly, these localised changes in neural activity are then relayed to sleep-regulating 5 
circuitry in the hypothalamus, brainstem and forebrain resulting in sleep [41].  6 
In addition, IL-1β and TNF–α indirectly affect sleep regulation through stimulating 7 
the activity of molecules which play regionally specific or generalised roles in the modulation 8 
of sleep architecture and duration, such as NF-κB, Gonadotropin-Releasing Hormone 9 
Receptor, Prostaglandin D2 and adenosine [6, 45]. Increased activity of these molecular 10 
entities can in turn form positive feedback loops, increasing activity of TNF-α and IL-1β, and 11 
eventually exerting cooperative inhibitory effects on wakefulness through promoting 12 
glutamatergic, dopaminergic, serotonergic, cholinergic, and gamma-aminobutyric acid 13 
(GABA)-ergic neuron activity in cortical and subcortical areas such as the basal forebrain, 14 
anterior hypothalamus, and the preoptic region [41, 46, 47]. 15 
It is important to point out that the release of these cytokines from astrocytes that may 16 
promote sleep is dependent on ‘information’ regarding the historical activity of local neurons. 17 
Such information is provided by intracellular levels of ATP which is released during 18 
neurotransmission and hence acts as a surrogate marker of past neural activity [48, 49]. 19 
Increased levels of ATP activate purinergic P2X7 receptors on proximate astrocytes and 20 
microglia, thereby inducing the synthesis and release of IL-1β and TNF-α together with ATP. 21 
This ATP is almost immediately hydrolysed to adenosine by intracellular adenosine kinase, 22 
which acts cooperatively on local neurons to promote sleep pressure as described above [50].  23 
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2.2.  The role of adenosine and adenosine receptors in the homeostatic regulation of 1 
sleep 2 
An accumulating body of evidence confirms the indispensable role played by 3 
astrocytes in the regulation of REM and slow wave sleep (SWS) homeostasis in mammals. 4 
Briefly, prolonged wakefulness increases intracellular levels of adenosine which acts on 5 
neuronal A1 and A2 adenosine receptors. These neuroreceptors modulate patterns of input 6 
and output at the local network and circuit levels leading to the state shift described as sleep 7 
[51]. These increased levels of adenosine in the intracellular space result from increased ATP 8 
exocytosis in response to increased neuronal activity, as indicated by fluctuations in calcium 9 
ion and glutamate levels in the intracellular space resulting from NMDA receptor activation 10 
detected by PX27 receptors on the surface of these glial cells [52-55]. 11 
The process underpinning the exocytosis of gliotransmitters from astrocytes, namely 12 
vesicular fusion, is enabled by the interaction and fusion of regulatory sec1/Munc18-like 13 
proteins and a range of N-ethylmaleimide-sensitive factor attachment protein receptors 14 
(SNAREs), synaptobrevin (also referred to as vesicle-associated membrane protein  or 15 
VAMP), syntaxin and synaptosomal-associated protein (SNAP)-25 with VAMP being 16 
located in vesicular membranes and syntaxin and SNAP-25 being located in plasma 17 
membranes [56, 57]. Finally, astrocytic SNARE signalling plays a paramount role in the 18 
regulation of sleep homeostasis [58, 59]. Figure 2 depicts the role of neuron-glial interactions 19 
involved in the regulation of sleep homeostasis. 20 
<Please insert Figure 2 here> 21 
2.3.  The role of Nitric oxide in the homeostatic regulation of sleep 22 
The contribution of nitric oxide (NO), synthesised by neuronal nitric oxide synthase (nNOS), 23 
in the homeostatic regulation of REM and to a lesser extent slow wave sleep (SWS) is well 24 
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documented (reviewed in [60]). nNOS is widely distributed in the central nervous system 1 
either in sparse interneurons or adjacent to circumscribed neuronal sets.  The mechanisms by 2 
which nNOS/NO regulate sleep remain to be fully delineated but would appear to involve the 3 
activation of guanylate cyclase resulting in the production of cyclic guanosine 4 
monophosphate (cGMP) [60]. Moreover, some evidence suggests that NO up-regulates 5 
adenosine A1 receptors on neurons pointing to a potential synergistic role between reactive 6 
nitrosative species and adenosine in the regulation of sleep homeostasis [61].  7 
There is a growing body of evidence to suggest that both nNOS and inducible nitric 8 
oxide synthase (iNOS) play complementary roles in the restoration of sleep duration and 9 
architecture following prolonged wakefulness with iNOS playing a major role in the 10 
restoration of NREM sleep and nNOS playing the dominant role in the restoration of REM 11 
sleep [62]. In addition, NO and iNOS levels in the basal forebrain increase in line with 12 
adenosine levels during sleep deprivation and it has been suggested that iNOS is involved in 13 
the release of adenosine from glial cells since inhibition of this enzyme leads to reduced 14 
levels of adenosine [62]. However, adenosine acting as a second messenger has the capacity 15 
to activate NF-κB which may be another molecular player involved in sleep promotion, while 16 
NF-κB activation may increase iNOS expression [9, 63]. Furthermore, iNOS production by 17 
astrocytes and microglial cells under (neuro)inflammatory conditions is also thought to be a 18 
major driver of increased SWS secondary to peripheral immune activation [60], which we 19 
will now discuss in more depth. 20 
Section 3. The relationship between inflammation, oxidative stress and sleep disruption 21 
Several research teams have reported increased levels of inflammatory markers such as IL-22 
1β, TNF-α IL-6 and IL-17 in the periphery following acute or chronic sleep deprivation (e.g. 23 
[64, 65]). The mechanisms underpinning this phenomenon include activation of signal 24 
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transducer and activator of transcription 1 (STAT1) and STAT3 in macrophages, increased 1 
Toll-like receptor 4 (TLR-4) activation of monocytes [64, 66] and modulation of gene 2 
expression in the autonomous circadian clocks of macrophages and NK cells following sleep 3 
deprivation-induced activation of NF-κB [67]. 4 
The duration of such effects following sleep restoration seem to vary for each specific 5 
cytokine, with IL-1 and IL-6 levels normalising rapidly following sleep recovery, while TNF-6 
α and IL-17 remain elevated long after the normalization of sleep patterns (reviewed in  [68]). 7 
Moreover, SD also results in profound changes in the activity and numbers of peripheral 8 
mononuclear blood cells (PMBCs) [69]. In brief, T and B cell numbers appear to remain 9 
stable following acute SD, whereas the activity and numbers of macrophages and neutrophils 10 
increase [70, 71].  Nevertheless, the activity and numbers of these latter PMBCs decrease 11 
rapidly following sleep restoration, but curiously numbers and activity of B and natural killer 12 
cells may increase during this time [65, 68]. 13 
 14 
 15 
3.2 Peripheral inflammation as a mechanism of impaired sleep homeostasis 16 
Peripheral inflammation as evidenced by increased levels of pro-inflammatory cytokines 17 
(PICs) is communicated to the brain via several routes. These include vagus nerve 18 
innervation, cytokine transport across the blood brain barrier (BBB) enabled by specific 19 
receptors, activation of perivascular macrophages and endothelial cells within the BBB, and 20 
finally via passive transport via circumventricular organs bereft of a functional BBB [72]. 21 
These transduced inflammatory signals lead to the activation of microglia and astrocytes with 22 
the subsequent release of PICs, notably TNF-α and IL-1β, chemokines, reactive oxygen 23 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
13 
 
species, prostaglandins, NO, cyclooxygenase-2, adenosine and a range of other inflammatory 1 
and signalling molecules [73, 74]. Experimental evidence gleaned from healthy human 2 
volunteers involving intravenous administration of inflammatory mediators such as 3 
lipopolysaccharides (LPS) revealed a significant reduction in the duration of REM sleep and 4 
a significant increase in the duration NREM sleep [75, 76]. These observations are consistent 5 
with data from rodent experiments where administration of IL-1 and TNF-α produced 6 
increased NREM sleep (Reviewed in [77]). Therefore, elevated levels of IL-1 and TNF-α in 7 
the brain due to activated immune and inflammatory pathways in the periphery could disturb 8 
sleep homeostasis. 9 
It should also be noted that other disruptors of sleep homeostasis stem from mediators 10 
released from activated microglia and the subsequent development of astrogliosis. This latter 11 
phenomenon leads to the overproduction of adenosine kinase thereby reducing the 12 
availability of adenosine in the intracellular space [78]. The release of COX-2, Prostaglandin 13 
D2 (PGD2) and PGE2 also appear to contribute to the development of sleep dyshomeostasis 14 
[79, 80]. Perhaps the greatest influence stems from the production of ROS and RNS species 15 
and the subsequent development of oxidative and nitrosative stress, which we will now 16 
consider. 17 
 18 
3.3. Oxidative and nitrosative stress as drivers of impaired sleep homeostasis  19 
Oxidative and nitrosative stress can disrupt sleep homeostasis either directly or indirectly via 20 
a number of different mechanisms. One straightforward mechanism involves the oxidative 21 
inactivation of cGMP which mediates the effects of NO on sleep homeostasis [81], while the 22 
up-regulation of NF-KB by iNOS secreted from activated microglia as discussed above also 23 
plays a major role in regulating sleep architecture [82]. Indirect mechanisms, such as the 24 
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inactivation of key proteins involved in sleep regulation, the modulation of ATP exocytosis 1 
from astrocytes, as well as NMDA-mediated neurotransmission require more explanation. 2 
Many cellular proteins such as those facilitating exocytosis of ATP discussed above 3 
are subject to redox regulation by reversible S-nitrosylation of key cysteine thiols, which play 4 
indispensable roles in enabling their function along multiple dimensions [83]. Under 5 
physiological conditions, fluctuations in NO levels provoke reversible changes in 6 
nitrosylation levels within the cellular proteome, which thereby plays a pivotal role in cellular 7 
homeostasis at least partly via the redox regulation of enzyme cascades and signal 8 
transduction pathways [84]. However, increased levels of NO and long-lasting nitrosative and 9 
oxidative stress leads to the breakdown of mechanisms enabling the reversibility of S-10 
nitrosylation [85, 86] driving the pathogenic state of protein hypernitrosylation, which in turn 11 
alters protein function [87]. 12 
In physiological conditions, NO decreases exocytosis via the s-nitrosylation of key 13 
cysteine groups within the tertiary structure of N-ethylmaleimide-sensitive factor (NSF) 14 
thereby inhibiting NSF-mediated SNARE disassembly [88]. In a state of hypernitrosylation, 15 
such inhibition would potentially be chronic. Moreover, the denitrosylation of NSF by 16 
thioredoxin may increase the rate of exocytosis [89]. However, in an environment of chronic 17 
nitrosative and oxidative stress, mechanisms enabling thioredoxin-mediated denitrosylation 18 
become inactivated, further compromising exocytotic processes [85]. Exocytosis may be 19 
further impaired by the binding of Munc-18-1 to syntaxin 1a in its closed conformation, 20 
which is inhibited in an environment of chronic nitrosative stress due to the S-nitrosylation of 21 
a cysteine residue (Cys 145) of syntaxin 1a [90].  22 
Dynamin is another major regulatory protein involved in the exocytotic process 23 
primarily via the release of vesicles from the membrane (reviewed by Jackson, Papadopulos, 24 
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Meunier, McCluskey, Robinson, Keating [91]). Interestingly the activity of this protein is 1 
also inhibited by S-nitrosylation at Cys 86 and Cys 607 [92]. The nitrosylation and 2 
subsequent inhibition of the NR2 subunit of the NMDA receptor at Cys 399 is perhaps the 3 
most well documented example of the inhibitory effects of NO on glutaminergic 4 
neurotransmission [93]. The subsequent suppression of NMDA activity [94] could be 5 
especially relevant in this context as optimal functioning of this receptor is a crucial element 6 
in the regulation of sleep homeostasis as discussed above.  7 
NMDA and other postsynaptic receptors involved in the maintenance of sleep 8 
homeostasis are housed in high postsynaptic density regions supported by a scaffolding 9 
protein referred to as postsynaptic density-95 (PSD-95). This mechanism modulates post-10 
synaptic activity by changing density of NMDA receptors in the post-synaptic cell 11 
membrane. The activity of PSD-95 in physiological conditions is also regulated by reversible 12 
nitrosylation, which decreases its overall activity and hence leads to a reduction in NDMA 13 
receptor density at the post-synaptic membrane [95]. S-nitrosylation of Stargazin and N-14 
ethylmaleimide sensitive factor (NSF) may also modulate the activity of NDMA receptors by 15 
altering the density of glutamatergic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 16 
(AMPA) receptors at the post-synaptic membrane [88, 96].  17 
It should also be noted that the function of NDMARs can also be compromised by the 18 
nitration of tyrosine residues normally playing an indispensable role in the structure and/or 19 
function of NDMA receptor subunit proteins [97]. Such nitration occurs due to high levels of 20 
peroxynitrite (ONOO−) formed by a reaction between NO and superoxide anions in a milieu 21 
of chronic oxidative and nitrosative stress [97]. ONOO− can also directly impair exocytosis 22 
via nitration of key tyrosine residues of SNAP-25, mammalian uncoordinated-18 (Munc18), 23 
synaptophysin and dynamin [98-100]. This is important from the perspective of putative 24 
treatments aimed at restoring sleep homeostasis as tyrosine nitration is considered by some 25 
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authors to be irreversible [101]. It is noteworthy that NDMAR activity is also an essential 1 
element in the regulation of the master circadian clock in the suprachiasmatic nucleus (SCN) 2 
[102]. Hence impaired function of this receptor could be one element in the chronic 3 
dysregulation of the circadian system apparently stemming from CSD [10]. Given 4 
bidirectional communication between circadian clock activity and de facto sleep-wake cycles, 5 
the same drivers of CSD in the periphery may also be involved in the concomitant 6 
dysregulation of circadian clock activity as we will now consider. 7 
 Section 5.  Inflammation, oxidative stress and dysregulation of circadian clocks 8 
Circadian and immune systems engage in a bidirectional interplay with several immune 9 
pathways being under circadian control; and inflammatory cascades are exacerbated by 10 
disruptions in the activity of the circadian clock [103]. On the other hand, immune and 11 
inflammatory mediators have the capacity to modulate the activity of central and peripheral 12 
circadian clock pathways via direct action on CLOCK (Circadian Locomotor Output Cycles 13 
Kaput), PER (Period) and other genes governing circadian clock activity [103]. For example, 14 
chronic peripheral inflammation evidenced by elevated PICs results in changes in clock gene 15 
expression [104] .  16 
SCN physiology can also be modulated by infections and elevated levels of TNF-α 17 
and IL-1β, which also disrupt sleep architecture as discussed above. The effects of immune 18 
activation on the SCN are probably mediated by the actions of TNF-α and IL-1β on their 19 
receptors which have been detected in the SCN [105]. Interestingly, cytokines and other 20 
immune stimuli also display the capacity to modify the phase of the SCN circadian clock 21 
[106]. The direct secretion of IL-1 and TNF-α from activated astrocytes within the SCN 22 
appears to play a particularly relevant role: these cytokines can regulate circadian clock 23 
activity by inhibiting the transcription of BMAL-1/CLOCK (see Figure 3), via a mechanism 24 
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which is dependent on p38/MAPK and calcium ion signalling [107]. In addition, these 1 
cytokines may regulate the transcription of PER-1, PER-2 and CRY-1, thereby increasing the 2 
activity of inhibitory proteins [108]. Increased levels of TNF-α also leads to the activation of 3 
the NF-κB signalling pathway, which also plays a major role in the disruption of circadian 4 
clock activity and is a source of oxidative and nitrosative stress [108, 109]. 5 
<Please insert Figure 3 here> 6 
5.2 Chronic oxidative and nitrosative stress as a mechanism of circadian dysregulation 7 
There is considerable evidence that the cellular redox state influences neuronal activity   and 8 
the transcription of clock genes within the SCN. This provides a route whereby ROS and 9 
RNS secreted by activated microglia and astrocytes can also disrupt the function of the 10 
master clock [110]. Importantly, the coordinated cross-talk between the circadian clock and 11 
the cellular redox state is essential to the optimal function of the former, hence chronic 12 
oxidative stress can provoke the long-lasting disruption of circadian rhythms [111]. The 13 
mechanisms whereby oxidative and nitrosative stress (O&NS) can lead to the deregulation of 14 
circadian clock activity are varied and complex. However, in principle O&NS deregulates the 15 
expression and signalling of molecules which play a crucial regulatory role in cellular 16 
metabolism such as adenosine monophosphate kinase (AMPK), and also promote the 17 
oxidative inactivation of non- transcriptional oscillators such as the peroxiredoxin system via 18 
over oxidation of crucial cysteine residues (Figure 3) [112]. In addition, evidence indicates 19 
that, once initiated, circadian system dysregulation could compromise cellular antioxidant 20 
defences governed by nuclear factor E2-related factor 2 (nrf-2) and the glutathione system 21 
and thus be an independent driver of increased O&NS in conditions like CFS, bipolar 22 
disorder, and MS [113].  23 
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It is also worth noting that there is also considerable data, mainly from animal studies, 1 
that sleep disruption per se can lead to increased levels of oxidative stress, which is 2 
unsurprising given the role of sleep in redox homeostasis and repairing oxidative damage to 3 
tissue (Reviewed in [114]). Hence this could also make a direct contribution to the 4 
maintenance or exacerbation of symptomology even if peripheral inflammation and oxidative 5 
stress was initially responsible for the development of both phenomena. This is also true for 6 
the relationship between sleep deprivation and peripheral inflammation, as the development 7 
of sleep disturbances could well initially stem from chronic systemic inflammation, and such 8 
disturbances would in turn be expected to exacerbate systemic inflammation over time. While 9 
we have discussed inflammation and O&NS separately as a vehicle for examining the effects 10 
of each parameter, these abnormalities invariably co- occur (reviewed in ref. [109]). These 11 
data suggest that targeting either immune or O&NS pathways may improve sleep dysfunction 12 
in neuro-immune disorders, while the amelioration of sleep and circadian aberrations in these 13 
disorders may improve underlying immune and O&NS abnormalities. Before discussing 14 
treatment options, however, we will review evidence regarding impaired sleep homeostasis in 15 
CFS, bipolar disorder and MS from the point of view of our hypothesis and emphasising 16 
supportive and contradictory data. 17 
 18 
 19 
 20 
Section 6.  Evidence of impaired sleep homeostasis in CFS, bipolar disorder and MS 21 
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In the section below we provide an overview of available evidence of sleep abnormalities in 1 
individuals with CFS, BD, and MS. Please refer to the Supplementary Material (on line) for a 2 
wider discussion. 3 
6.1 Impaired sleep homeostasis in CFS  4 
Many patients with a diagnosis of CFS report profound disturbances in sleep patterns and 5 
unrefreshing sleep is one of the characteristic symptoms of CFS [31]. Early studies 6 
investigating patients meeting diagnostic criteria for CFS reported that over half their study 7 
population displayed sleep abnormalities such that they would qualify for a diagnosis of a 8 
primary sleep disorder, but  that their overall assessment led them to conclude that these sleep 9 
abnormalities were part of the syndrome and not evidence of a primary sleep disorder per se 10 
[115]. However, other studies using wider definitions reported that fewer patients met criteria 11 
for a primary sleep disorder or even found no objective evidence of any sleep disorder 12 
whatsoever (e.g. [116]). Studies examining the nature of these sleep disturbances have 13 
reported objective measures of worse sleep efficiency, increased durations of awakening and 14 
increased sleep latency in at least a meaningful subset of participants with CFS [117]. 15 
Readers interested in a more detailed treatment of evidence relating to sleep 16 
disturbances in patients afforded a diagnosis of CFS and how far variance in diagnostic 17 
criteria and etiological heterogeneity can explain the findings of different authors are invited 18 
to consult recent reviews on the topic [63]. The mechanisms driving sleep disturbances in 19 
CFS patients may well be multiple, but systemic inflammation as a result of increased 20 
bacterial translocation is a promising candidate in at least a subgroup of patients. Commensal 21 
bacteria additionally synthesize neurotransmitters, and affects balance of short chain fatty 22 
acids, including butyrate, which can cause changes in immunoinflammatory pathways, in 23 
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addition to inducing the translocation of bacteria into the bloodstream and subsequent LPS-1 
induced inflammation [40, 118, 119]. 2 
6.2. Impaired sleep homeostasis in bipolar disorder 3 
Sleep disturbances are part of the diagnostic criteria for bipolar disorder  (BD) [120], and 4 
have been associated with poor prognosis, significantly reduced quality of life, impaired daily 5 
functioning, and increased global symptom burden, while treatment of insomnia may 6 
improve mood symptoms and functioning in BD  [121, 122]. Sleep disturbances in patients 7 
with bipolar disorder may occur prior to the onset of mood episodes, and are exacerbated 8 
through the course of the episode [123]. Extensive literature reviews indicate that the pattern 9 
of sleep disruption varies between patients in bipolar mania compared to those experiencing 10 
bipolar depression (e.g.[30]).  11 
 Circadian clock dysregulation is often cited as a possible driver of at least some sleep 12 
disturbances observed across the mood spectrum in bipolar disorder [124]. In addition, other 13 
abnormalities known to be associated with the pathophysiology of BD such as O&NS [125] 14 
and increased levels of PICs in acute mood states of BD (IL-6, TNF-α, C-reactive protein) as 15 
well as in euthymia (IL-1β) [126], have the capacity to induce abnormalities in the circadian 16 
clock, downstream gene transcription, and provoke disruptions in mechanisms regulating 17 
sleep homeostasis, as discussed above.  Moreover, nitric oxide levels increase during manic 18 
episodes [127]. However, the role of O&NS and peripheral inflammation as possible 19 
mechanisms underpinning circadian sleep aberrations in BD warrant further investigation. 20 
 21 
 22 
6.3. Impaired sleep homeostasis in MS 23 
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The prevalence of disturbed sleep patterns in MS patient populations is approximately 62%, 1 
[28]. The debilitating effect of poor sleep quality in MS patients is highlighted by the work of 2 
Merlino, Fratticci, Lenchig, Valente, Cargnelutti, Picello, et al. [128] who demonstrated that 3 
disability levels as measured by the Expanded Disability Status Scale was associated with the 4 
degree of sleep deprivation. 5 
 The pathophysiology of these symptoms is not fully understood although circadian 6 
rhythm disorders and elevated PIC levels have been proposed as possible drivers of impaired 7 
sleep homeostasis in MS patients [67, 129]. However, sleep disruption may also stem from 8 
the use of immunotherapy and other factors such as lesion load. In addition, co-occurring 9 
mental disorders (e.g. BD and MDD) [130] may also contribute to the occurrence of sleep 10 
disturbances in a meaningful subset of patients with MS. Thus, the underlying 11 
pathophysiology of sleep disturbances in MS patients seems to be multifactorial and 12 
relatively complex. 13 
6.4 Therapeutic options for restoration of sleep homeostasis in neuro-immune and 14 
neuroprogressive disorders 15 
Endogenous melatonin is a key regulator of circadian rhythms, and is a powerful anti-16 
oxidant [131]. Melatonin has also been effectively used to treat CFS in patients with MS, 17 
decreasing oxidative and nitrosative markers such as plasma lipid hydroxyperoxides [132]. 18 
Current evidence of melatonin as treatment for bipolar disorder, however, is scant. Melatonin 19 
acts as a potent ROS scavenger, antioxidant and a positive modulator of mitochondrial 20 
performance [133]. Furthermore, melatonin exerts a range of pleiotropic effects on the 21 
immune system which are either pro-inflammatory or anti-inflammatory. The pro-22 
inflammatory effects predominate when the immune system functions at a basal level, but the 23 
anti-inflammatory effects predominate in an environment of activated immune and 24 
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inflammatory pathways [134]. In the latter environment, there is copious in vivo evidence 1 
demonstrating that melatonin administration attenuates TLR-4 mediated inflammatory 2 
responses stemming from the activation of myeloid differentiation primary response gene 88 3 
or TIR-domain-containing adapter-inducing interferon-β (TRIF), particularly when TLR-4 4 
receptors are activated by commensal LPS [135, 136]. These anti-inflammatory effects may 5 
underpin the promising results obtained from studies investigating the use of melatonin in 6 
animal models of neurodegenerative diseases and are the motivation for an increased focus of 7 
the use of this molecule as a therapeutic agent targeting the pathophysiology of neuro-8 
immune and neurodegenerative diseases. In addition, several lines of evidence indicate that 9 
melatonin may offer beneficial sleep-promoting effects (see Supplementary online material 10 
for a wider discussion). 11 
Hydrogen has been proposed as a potential adjunctive therapy for neuropsychiatric 12 
illnesses such as PD, as oxidative stress appears to be one of many factors involved in their 13 
pathophysiology[137]. In preclinical models of PD, hydrogen water administration decreases 14 
levels of oxidative stress markers, and displayed neuroprotective properties [138]. However, 15 
no study to date has looked at the effects of molecular hydrogen as a sleep intervention in PD 16 
or CFS, and though molecular hydrogen has been proposed as an adjunctive treatment for 17 
bipolar disorder [139], no study to our knowledge has yet to explore this treatment avenue. 18 
The use of molecular hydrogen as a treatment for sleep homeostasis is an intriguing 19 
proposition, as the molecule readily crosses the BBB and appears to have minimal side 20 
effects [140]. The anti-inflammatory effects of molecular hydrogen in reducing levels of 21 
TNF-α, IL-1β and IL-6 have been demonstrated in a number of human and animal studies. 22 
Interestingly, this effect appears to be mediated at least in part by inhibiting the activation of 23 
NF-KB by TNF-α [141]. Molecular hydrogen also appears to mitigate oxidative damage to 24 
the brain by quenching damaging effects of ROS, most notably hydroxyl radicals [142]. 25 
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Given these putative mechanisms of action, molecular hydrogen should be investigated as an 1 
adjunctive treatment avenue for bipolar disorder and CFS. Please refer to the Supplementary 2 
Material (available online) for a wider discussion of potential therapeutic strategies for sleep 3 
dysfunction across neuro-immune disorders. 4 
Conclusion and future directions 5 
This review indicates that neuro-immune and neuroprogressive diseases such as CFS, BD and 6 
MS are often accompanied by significant sleep and circadian abnormalities. These 7 
abnormalities may aggravate the course and overall disability attributed to these disorders 8 
although more prospective studies are warranted. Furthermore, O&NS and immune 9 
aberrations may contribute to the emergence of sleep disturbances across neuro-immune 10 
disorders. In addition, sleep dysfunction may aggravate O&NS, mitochondrial dysfunction, 11 
immune activation, and (neuro) inflammation associated with these disorders in a vicious 12 
pathophysiological loop.  13 
Practice Points: 
The interplay of inflammatory and oxidative stress mechanisms in sleep dysfunctions may: 
 1.Provide an interface of mechanisms involved in neuro-immune pathways in multiple 
sclerosis, bipolar disorder and chronic fatigue syndrome; 
 2.Combine into complex abnormalities which may aggravate the course and overall 
disability attributed to these disorders; 
 3.Provide novel treatments strategies to address these diverse sleep abnormalities trans-
diagnostically. 
Research Agenda: 
Future directions: 
1. Confirm the hypothesis that sleep dysfunction may exacerbate oxidative and nitrosative 
stress, mitochondrial dysfunction, immune activation, and (neuro) inflammation associated 
with these disorders in a vicious pathophysiological loop. 
2. Further investigation of chronotherapeutic, anti-oxidant and anti-inflammatory treatment 
strategies, such as melatonin and molecular hydrogen in preclinical and clinical studies of 
bipolar disorder, multiple sclerosis and chronic fatigue syndrome 
 3. Specific targeted treatments for sleep abnormalities in these neuropsychiatric conditions 
within the context of precision medicine are clearly awaited. 
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Legend to the Figures 1 
Figure 1. Chronic sleep deprivation (CSD) which is a frequent manifestation of neuro-2 
immune diseases (e.g. CFS, BD and MS) has several detrimental effects on 3 
oxidative/nitrosative, mitochondrial, and immune-inflammatory pathways. CSD may reduce 4 
the expression of electron transport chain complexes in the prefrontal cortex, hippocampus, 5 
striatum, and hypothalamus. In addition, CSD may uncouple oxidative phosphorylation from 6 
ATP generation, and may also promote the so-called endoplasmatic reticulum (ER) unfolded 7 
protein response. Furthermore, CSD may increase peripheral levels of pro-inflammatory 8 
cytokines (e.g., IL-1β and TNF-α). Peripheral inflammation may in turn promote (neuro) 9 
inflammation and microglial activation. CSD may also alter the number (∆), morphology and 10 
function of glial cells. Finally, CSD may decrease the expression of the glutamate NMDA 11 
receptor at post-synaptic membranes, thereby decreasing neurogenesis. 12 
Figure 2. Wakefulness promotes the release of ATP, which activates the purinergic P2X7 13 
receptor leading to the exocytosis of immune mediators (including pro-inflammatory 14 
cytokines) as well as ATP from microglia and activated astrocytes. The release of 15 
gliotransmitters is mediated by a process referred to as vesicular fusion and involves 16 
interactions with several proteins (e.g. Sec1/Munc18- like and SNARES). Inflammatory 17 
cytokines may activate the NF-κB pathway and increase the expression of adenosine, GHRH 18 
and PGD2. These mediators influence the firing of glutamatergic (Glut), dopaminergic (DA), 19 
serotoninergic (5-HT), and GABAergic neurons in areas involved in sleep regulation (e.g. 20 
hypothalamus and brainstem).   Adenosine may also activate cognate A1 and A2 receptors, 21 
thereby increasing sleep pressure. 22 
Figure 3. Sleep deprivation may activate astrocytes in the suprachiasmatic nucleus (SCN) 23 
leading to the production of pro-inflammatory cytokines like IL-1β and TNF-α, which 24 
activate their receptors, IL-1R and TNR, respectively. Activated astrocytes in the SCN may 25 
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have an increased expression of period circadian clock (PER) 1 and 2, as well as circadian 1 
clock protein cryptochrome 1 (CRY-1) genes, which may inhibit CLOCK/BmaI1expression. 2 
In addition, these cytokines may also the p35 MAPK and calcium pathways, further 3 
inhibiting BmaI1/CLOCK expression in the SCN. Sleep deprivation also leads to oxidative 4 
and nitrosative stress (O&NS), which deregulates the expression of adenosine 5 
monophosphate kinase (AMPK) and non-transcriptional oscillators like the peroxizedoxin 6 
system, which may further contribute to circadian dysregulation. Sleep deprivation also 7 
increase the production of nitric oxide (NO), which drives the nitrosylation of key proteins 8 
like the N-ethylmaleimide sensitive factor (NSF) and postsynaptic density-95 (PD-95), thus 9 
altering the function and expression of glutamatergic AMPA and NMDA receptors. These 10 
mechanisms further deregulate SCN function, leading to circadian abnormalities. 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
 21 
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